

APASL STC 2026 Kumamoto Program at a Glance

Day 1 September 18 (Friday) 2026

	September 18 (Friday) 2026				
	Room 1	Room 2	Room 3	Poster	
	Registration				
08:50-09:00	8:50-9:00 Opening Remarks				
09:00-09:10	9:00-9:20 State of the Art Lecture I Dr. Chien-Jen Chen	9:00-9:20 State of the Art Lecture III Dr. Hiroyoshi Nishikawa	9:00-10:20 Session 4 Cutting Edge in Basic Research of Steatotic Liver Diseases (MASLD/MAFLD and ALD)	Poster Viewing	
09:10-09:20		9:20-9:40 State of the Art Lecture II Dr. Kiyohiko Izumi			
09:20-09:30	9:20-10:40 Session 2 Cutting Edge in Liver Cancer Research: Molecular Mechanisms and Therapeutic Targets				
09:30-09:40					
09:40-09:50					
09:50-10:00					
10:00-10:10					
10:10-10:20					
10:20-10:30					
10:30-10:40					
10:40-10:50					
10:50-11:00					
11:00-11:10					
11:10-11:20					
11:20-11:30	11:20-11:50 Keynote Lecture I Dr. Jia-Horng Kao		10:50-12:20 Session 3 Advances in the Epidemiology and Diagnosis of Hepatocellular Carcinoma		
11:30-11:40					
11:40-11:50	11:50-12:20 Keynote Lecture II Dr. Makoto Nakanishi				
11:50-12:00					
12:00-12:10					
12:10-12:20					
12:20-12:30					
12:30-12:40					
12:40-12:50	12:30-13:30 Luncheon Seminar 1 [Gilead Sciences K.K.]	12:30-13:30 Luncheon Seminar 2 [Chugai Pharmaceutical Co., Ltd.]	12:30-13:30 Luncheon Seminar 3 [Boehringer Ingelheim GmbH]		
12:50-13:00					
13:00-13:10					
13:10-13:20					
13:20-13:30					
13:30-13:40					
13:40-13:50	13:40-14:10 Keynote Lecture III Dr. Hiroaki Mitsuya	13:40-13:55 Special Lecture Dr. Masao Omata	13:40-14:10 Plenary Session		
13:50-14:00		13:55-14:15 State of the Art Lecture IV Dr. Jacob George			
14:00-14:10					
14:10-14:20					
14:20-14:30	14:10-15:30 Session 6 Cutting Edge in HBV Research: From Basic Virology to Pathogenesis	14:15-15:30 Session 8 Future Directions in the Management of MASH: Integrating Emerging and Novel Therapeutic Strategies	14:10-15:30 IASL-APASL STC Joint Symposium: HBV Diagnosis and Treatment in Asia: From Biomarkers to the Indeterminate Grey Zone and HCC Management		
14:30-14:40					
14:40-14:50					
14:50-15:00					
15:00-15:10					
15:10-15:20					
15:20-15:30					
15:30-15:40					
15:40-15:50	15:45-16:45 Sponsored Seminar 1 [GlaxoSmithKline K.K.]	15:45-16:45 Sponsored Seminar 2 [AbbVie GK]	15:45-16:45 Sponsored Seminar 3 [Fujirebio, Inc.]		
15:50-16:00					
16:00-16:10					
16:10-16:20					
16:20-16:30					
16:30-16:40					
16:40-16:50					
16:50-17:00					
17:00-17:10	16:55-17:55 Session 7 Novel Biomarkers in HBV: Clinical Utility and Future Prospects	16:55-18:10 Session 9 HCV-Related HCC in the Post-SVR Era: Risk Assessment and Surveillance	16:55-17:55 Evening Seminar [Eisai Co., Ltd.]	Poster Session 16:55-18:55	
17:10-17:20					
17:20-17:30					
17:30-17:40					
17:40-17:50					
17:50-18:00					
18:00-18:10					
18:10-18:20					
18:20-18:30					
18:30-18:40					
18:40-18:50					
18:50-19:00					
19:00-19:10	19:00-21:00 Awarding Ceremony Welcome Reception				
19:10-19:20					
19:20-19:30					
19:30-19:40					
19:40-19:50					
19:50-20:00					
20:00-20:10					
20:10-20:20					
20:20-20:30					
20:30-20:40					
20:40-20:50					
20:50-21:00					

*The program is subject to change.

APASL STC 2026 Kumamoto Program at a Glance

Day 2 September 19 (Saturday) 2026

	September 19 (Saturday) 2026				
	Room 1	Room 2	Room 3	Poster	
08:00-08:10	08:00-9:00 Morning Seminar 1 [Taisho Pharmaceutical Co., Ltd.]	08:00-9:00 Morning Seminar 2 [Fujirebio, Inc.]	08:00-9:00 Morning Seminar 3 [Miyarisan Pharmaceutical Co., Ltd.]		
08:10-08:20					
08:20-08:30					
08:30-08:40					
08:40-08:50					
08:50-09:00					
09:00-09:10				Poster Viewing	
09:10-09:20	09:10-9:30 State of the Art Lecture V Dr. Masatoshi Kudo	09:10-10:40 Session 11 Current Standards and Controversies in the Management of Chronic Hepatitis B	Free Papers		
09:20-09:30	09:30-11:00 Session 10-1 Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy				
09:30-09:40					
09:40-09:50					
09:50-10:00					
10:00-10:10					
10:10-10:20					
10:20-10:30					
10:30-10:40			10:30-10:50 State of the Art Lecture VI Dr. Takahiro Ochiya		
10:40-10:50		10:50 -12:20 Session 13 Cutting Edge in Cirrhosis Research: Mechanisms of Regeneration and Fibrosis Reversal			
10:50-11:00	10:50-12:20 Session 12 Novel Therapies for HBV: The Road to Functional Cure				
11:00-11:10					
11:10-11:20			11:10-12:20 Session 10-2 Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy		
11:20-11:30					
11:30-11:40					
11:40-11:50					
11:50-12:00					
12:00-12:10					
12:10-12:20					
12:20-12:30					
12:30-12:40	12:30-13:30 Luncheon Seminar 4 [GlaxoSmithKline K.K.]	12:30-13:30 Luncheon Seminar 5 [Bristol-Myers Squibb Company/ Ono Pharmaceutical Co., Ltd]	12:30-13:30 Luncheon Seminar 6 [Roche Diagnostics K.K.]		
12:40-12:50					
12:50-13:00					
13:00-13:10					
13:10-13:20					
13:20-13:30					
13:30-13:40					
13:40-13:50	13:40-14:10 Keynote Lecture IV Dr. Shiv K. Sarin	13:40-15:00 Session 15 Frontiers of Conversion Therapy for Advanced Hepatocellular Carcinoma	13:40-14:40 Session 16 Cutting Edge in Autoimmune Liver Disease (PBC/AIH/PSC): From Basic Science to Clinical Practice		
13:50-14:00					
14:00-14:10	14:15-15:35 Session 14 Cutting-Edge Advances in the Management of Cirrhosis and Portal Hypertension: Insights from Baveno Consensus		Free Papers		
14:10-14:20					
14:20-14:30					
14:30-14:40					
14:40-14:50			Free Papers		
14:50-15:00					
15:00-15:10					
15:10-15:20					
15:20-15:30					
15:30-15:40					
15:40-15:50	15:45-16:45 Sponsored Seminar 4 [Gilead Sciences K.K.]	15:45-16:45 Sponsored Seminar 5 [AbbVie GK]	Free Papers		
15:50-16:00					
16:00-16:10					
16:10-16:20					
16:20-16:30					
16:30-16:40					
16:40-16:50					
16:50-17:00	Free Papers	Free Papers			
17:00-17:10					
17:10-17:20					
17:20-17:30					
17:30-17:40	17:30-17:40 Closing Remarks				
17:40-17:50					
17:50-18:00					

*The program is subject to change.